gland pharma glp-1 capacity expansion capex Buy Ltd for the Target Rs 2,300 by Motilal Oswal Financial Services Ltd GLP-1 Receptor Agonist Market Growth

Semaglutide example (maintenance dose): Brand-name Wegovy: ~$1,350/month = ~$16,200/year Compounded (503B): ~$300/month average = ~$3,600/year Annual savings: approximately $12,600 Percentage savings: approximately 78% Tirzepatide example (maintenance dose): Brand-name Zepbound: ~$1,060/month = ~$12,720/year Compounded (503B): ~$375/month average = ~$4,500/year Annual savings: approximately $8,220 Percentage savings: approximately 65% Over a multi-year treatment course - and GLP-1 treatment is typically long-term - these savings compound dramatically

[PMC free article] [PubMed] [CrossRef] Mori T, Tsuchiyama A, Nagai K, Nagao M, Oyanagi K, Tsugawa S

The risk of vomiting, dehydration, and electrolyte imbalances climbs sharply

IGF-1 LR3 is a recombinant 83-residue IGF-1 analog with arginine substituted for glutamic acid at position 3 and an additional 13-residue N-terminal extension